CLINICAL RESEARCH

Effects of cimetidine and ranitidine on high density lipoprotein cholesterol concentrations

J A WILSON, I F CRAIG

Abstract

To assess the effect of cimetidine and ranitidine on high density lipoprotein (HDL) cholesterol concentration two groups of eight patients with duodenal ulcer or oesophagitis matched for age, sex, and cigarette consumption were given either cimetidine 1 g daily or ranitidine 300 mg daily for one month. There was no significant change in the cholesterol content of HDL and its subfraction HDL₃ after treatment with ranitidine or cimetidine, or in the cholesterol content of the subfraction HDL₂ after treatment with ranitidine; the HDL₂ cholesterol concentration was, however, significantly increased after treatment with cimetidine. Further studies are being undertaken to establish the mechanism of this effect.

Introduction

Cimetidine was recently reported as having caused an increase in high density lipoprotein (HDL) cholesterol concentration in a patient with type III hyperlipoproteinaemia.¹ A further study showed an increase in HDL cholesterol concentrations in 10 healthy volunteers after four weeks of treatment with cimetidine 1 g daily.² We examined the effect of cimetidine 1 g daily or ranitidine 300 mg daily on the concentrations of cholesterol in HDL and its subfractions HDL₂ and HDL₃.

Patients, methods, and results

A fasting blood sample was withdrawn from two groups of eight patients with duodenal ulcer or oesophagitis, matched for age, sex, and cigarette consumption. Liver function, as reflected by aspartate aminotransferase and γ -glutamyltranspeptidase activities, was normal. After one month of treatment with either cimetidine 1 g daily or ranitidine 300 mg daily, allocated in random fashion, a further

Individual changes in HDL₂ cholesterol concentration after one month's treatment in eight patients given cimetidine and eight given ranitidine. Horizontal bars indicate mean values; 95% confidence limits are also shown.

Conversion: SI to traditional units—Cholesterol: 1 mmol/l $\approx$ 38.6 mg/100 ml.

fasting sample was withdrawn. On each occasion the plasma was separated immediately and stored at 4°C and, within four days, HDL was precipitated sequentially with heparin-manganese and dextran sulphate of molecular weight 15 000 daltons, which isolated HDL_p and HDL_s (corresponding to HDL₂ and HDL₃).³ The cholesterol content of HDL, HDL₂, and HDL₃ was measured with a commercially available kit containing cholesterol oxidase and cholesterol esterase. Statistical analysis was undertaken with the Wilcoxon ranked sum test.

The table shows the results. Concentrations of HDL, HDL₂, and HDL₃ cholesterol were not significantly different after treatment

Ninewells Hospital, Dundee DD2 1UB

J A WILSON, MRCP, senior registrar
I F CRAIG, PHD, medical student

Correspondence to: Dr J A Wilson.

Median HDL cholesterol concentrations (and ranges) (mmol/l) before and after treatment with cimetidine or ranitidine

	Before treatment	After treatment	Significance
HDL cholesterol:			
Cimetidine	1.24 (0.91-1.75)	1.39 (0.87-2.19)	NS
Ranitidine	1.08 (0.85-2.20)	1.07 (0.84-2.23)	NS
HDL ₂ cholesterol:			
Cimetidine	0.21 (0.04-0.57)	0.42 (0.11-0.85)	p < 0.01
Ranitidine	0.29 (0.06-1.24)	0.26 (0.12-1.34)	NS
HDL ₃ cholesterol:			
Cimetidine	0.97 (0.85-1.18)	0.90 (0.76-1.14)	NS
Ranitidine	0.81 (0.63-0.96)	0.83 (0.66-1.01)	NS

Conversion: SI to traditional units—Cholesterol: 1 mmol/l $\approx$ 38.6 mg/100 ml.

with ranitidine, and concentrations of HDL and HDL₃ cholesterol were not significantly different after treatment with cimetidine. HDL₂ cholesterol concentrations were significantly raised, however, after treatment with cimetidine (p < 0.01) (figure).

Discussion

An increase in HDL₂ cholesterol can be explained either by an increase in the secretion of new particles into this density

range or by changes in metabolism leading to accumulation of HDL₂ without the need for de novo synthesis. We suggest two possible mechanisms: firstly, cimetidine has antiandrogenic properties, and HDL is related to testosterone concentrations⁴; secondly, cimetidine might activate lipoprotein lipase or lecithin cholesterol acyltransferase, both of which play a part in converting HDL₃ to HDL₂. The true explanation for these changes remains unclear, but, in view of the widely reported inverse relation between HDL₂ concentrations and accelerated ischaemic heart disease, this finding is potentially useful. Further studies are being undertaken to examine the mechanism of this effect.

References

- 1 Miller NE, Lewis B. Cimetidine and HDL cholesterol. *Lancet* 1983;i:529.
- 2 Bolton CH, Daneshmend TK, Ene MD, *et al.* The effects of cimetidine on serum and lipoprotein lipids in normal subjects. *Br J Clin Pharmacol* 1983;15:152.
- 3 Gidez LI, Miller GJ, Burstein M, *et al.* Separation and quantitation of subclasses of human plasma HDL by a simple precipitation procedure. *J Lipid Res* 1982;23:1206.
- 4 Furman RH, Alaupovic PJ, Howard RP. Effects of androgens and oestrogens on serum lipids and the composition of serum lipoproteins in normolipemia and hyperlipaemic states. *Prog Biochem Pharmacol* 1967;2:215-49.

(Accepted 13 December 1984)

Seroepidemiology of HTLV-III antibodies in a remote population of eastern Zaire

ROBERT J BIGGAR, MADS MELBYE, LUC KESTENS, MARC DE FEYTER, CARL SAXINGER, ANNE J BODNER, L PALUKO, WILLIAM A BLATTNER, PAUL L GIGASE

Abstract

A human retrovirus—human T cell lymphotropic virus-III (HTLV-III)—has recently emerged as the probable cause of acquired immunodeficiency syndrome (AIDS). In May 1984, 250 outpatients at a hospital in a remote area of eastern Zaire were surveyed for AIDS type illnesses and the prevalence of antibodies against HTLV-III determined by an enzyme linked immunosorbent assay using disrupted whole HTLV-III virus as the antigen. No clinical cases of AIDS were diagnosed among these patients.

Overall, 31 (12.4%) had clearly positive ratios (≥ 5.0) and a further 30 (12.0%) had borderline ratios ($3.0 < 5.0$). Western blots of serum samples from subjects with antibodies yielded bands consistent with HTLV-III as found in American patients with AIDS and members of groups at risk of AIDS. The prevalence of antibody was highest in childhood (p = 0.02); among adults prevalence rose slightly with age. HTLV-III antibodies were more common among the uneducated (p = 0.006), agricultural workers (p = 0.03), and rural residents (p = 0.06), but the Western blot bands were generally weak in this group. By contrast, one urban resident had strong bands.

The relatively high prevalence of antibodies among the rural poor in this area of Zaire suggests that HTLV-III or a closely related, cross reactive virus may be endemic in the region. A different natural history of infection, perhaps in childhood, may also explain the findings.

National Cancer Institute, Bethesda, Maryland, USA

ROBERT J BIGGAR, MD, medical epidemiologist

CARL SAXINGER, PHD, microbiologist

WILLIAM A BLATTNER, MD, chief of family studies section

Institute of Cancer Research, Aarhus, Denmark

MADS MELBYE, MD, medical staff fellow

Institute of Tropical Medicine, Antwerp, Belgium

LUC KESTENS, BSC, biologist

PAUL L GIGASE, MD, head of department of pathology

FOMULAC Hospital, Katana, Kivu District, Zaire

MARC DE FEYTER, MD, chief physician

L PALUKO, MD, internist

Biotech Research Laboratories Inc, Rockville, Maryland, USA

ANNE J BODNER, PHD, chief of serotesting

Correspondence to: Dr R J Biggar, Landow Building 3C19, Bethesda, Maryland, USA, 20205.

Introduction

Investigators have recently described a retrovirus that appears to be a causative for acquired immunodeficiency syndrome (AIDS).¹⁻⁴ This agent, a member of the human T cell lymphotropic virus (HTLV) family, has repeatedly been isolated from American and European patients with AIDS and subjects at risk of AIDS, most of whom also had detectable antibody against the agent.⁵⁻⁶ Prospective studies have confirmed that those with antibodies are more likely to develop AIDS.⁷⁻⁸ By contrast, fewer than 1% of healthy American blood donors have antibodies to the agent.^{5-8a}

AIDS has also been described in Africans⁹⁻¹³ and in Europeans who had a history of travel in Africa but no other risk